Immediate Impact
4 by Nobel laureates 2 from Science/Nature 58 standout
Citing Papers
Renal cell carcinoma
2024 Standout
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
2023 Standout
Works of S. Srinivas being referenced
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| S. Srinivas | 512 | 278 | 260 | 403 | 37 | 794 | |
| Marina D. Kaymakcalan | 359 | 409 | 210 | 255 | 31 | 881 | |
| Pier Vitale Nuzzo | 478 | 378 | 288 | 370 | 58 | 901 | |
| Ursula Vogl | 410 | 392 | 168 | 336 | 20 | 864 | |
| Philippe Montcuquet | 328 | 574 | 243 | 246 | 39 | 905 | |
| J. Wendall Goodwin | 326 | 513 | 100 | 185 | 34 | 984 | |
| Anne Flörcken | 448 | 316 | 225 | 349 | 61 | 862 | |
| Marija Bojić | 339 | 356 | 91 | 277 | 39 | 925 | |
| Thorsten Ruf | 479 | 377 | 141 | 178 | 20 | 775 | |
| Azzurra Onofri | 370 | 363 | 99 | 190 | 39 | 808 | |
| Yuanjue Sun | 391 | 418 | 135 | 308 | 40 | 918 |
All Works
Login with ORCID to disown or claim papers
Loading papers...